NCT05136144View on ClinicalTrials.gov

Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis

PHASE2UnknownINTERVENTIONAL

Enrollment

70

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

July 31, 2024

Conditions

Seborrheic Keratosis

Interventions

DRUG

SM-020

Topical Akt Inhibitor SM-020 Gel

Trial Locations (1)

Unknown

Zepeda Dermatologia, Santa Tecla

Sponsors

Lead Sponsor

DermBiont, Inc.

All Listed Sponsors

collaborator

Zepeda Dermatologia

UNKNOWN

lead

DermBiont, Inc.

INDUSTRY

NCT05136144 - Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis | Biotech Hunter | Biotech Hunter